These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37062018)

  • 1. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
    Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
    J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nusinersen treatment on quality of life and motor function in adult patients with spinal muscular atrophy.
    Şimşek Erdem N; Güneş Gencer GY; Alaamel A; Uysal H
    Neuromuscul Disord; 2024 Mar; 36():28-32. PubMed ID: 38310720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.
    Bonanno S; Zanin R; Bello L; Tramacere I; Bozzoni V; Caumo L; Ferraro M; Bortolani S; Sorarù G; Silvestrini M; Vacchiano V; Turri M; Tanel R; Liguori R; Coccia M; Mantegazza RE; Mongini T; Pegoraro E; Maggi L
    J Neurol; 2022 Jun; 269(6):3264-3275. PubMed ID: 34978620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis.
    Hagenacker T; Maggi L; Coratti G; Youn B; Raynaud S; Paradis AD; Mercuri E
    Neurol Ther; 2024 Oct; 13(5):1483-1504. PubMed ID: 39222296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
    Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
    Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nusinersen for adults with spinal muscular atrophy.
    Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study.
    Wang N; Hu Y; Jiao K; Cheng N; Sun J; Tang J; Song J; Sun C; Wang T; Wang K; Qiao K; Xi J; Zhao C; Yu L; Zhu W
    J Neurol; 2024 Sep; 271(9):6004-6014. PubMed ID: 39030456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment.
    Binz C; Schreiber-Katz O; Kumpe M; Ranxha G; Siegler H; Wieselmann G; Petri S; Osmanovic A
    J Neurol; 2021 Mar; 268(3):950-962. PubMed ID: 33029682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatigue in adults with spinal muscular atrophy under treatment with nusinersen.
    Kizina K; Stolte B; Totzeck A; Bolz S; Schlag M; Ose C; von Velsen O; Kleinschnitz C; Hagenacker T
    Sci Rep; 2020 Jul; 10(1):11069. PubMed ID: 32632203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
    Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
    J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function.
    Serrão C; Domingues S; de Campos CF; Moreira S; Conceição I; de Carvalho M; Oliveira Santos M
    Neurol Sci; 2024 Jun; 45(6):2887-2891. PubMed ID: 38589769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
    Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
    J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment-A Pilot Study.
    Thimm A; Brakemeier S; Kizina K; Munoz Rosales J; Stolte B; Totzeck A; Deuschl C; Kleinschnitz C; Hagenacker T
    Front Neurol; 2021; 12():812063. PubMed ID: 35140677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
    Yao X; Peng J; Luo R; Wang X; Lu X; Wu L; Jin R; Zhong J; Liang J; Hong S; Yang L; Zhang X; Mao S; Hu J; Tao Z; Sun D; Wang H; Zhang L; Xia Y; Chen K; Wang Y
    J Neurol; 2024 Aug; 271(8):5378-5391. PubMed ID: 38954034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.